AVM
VIR icon

Arch Venture Management’s Vir Biotechnology VIR Stock Holding History

Arch Venture Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$129M Sell
12,694,163
-222,500
-2% -$2.12M 11.76% 6
2026
Q1 		$116M Hold
12,916,663
– – 17.09% 3
2025
Q4 		$77.9M Hold
12,916,663
– – 11.95% 5
2025
Q3 		$73.8M Hold
12,916,663
– – 14.98% 4
2025
Q2 		$65.1M Buy
+12,916,663
New +$69.3M 21.76% 2

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Arch Venture Management's VIR Position: Q2 2026 in Review

Arch Venture Management reduced its Vir Biotechnology (VIR) stake by 1.7% in Q2 2026, selling an estimated $2.12M and leaving 12,694,163 shares worth $129M. The position accounts for 11.76% of the portfolio, ranked #6.

Arch Venture Management first reported a position in VIR in Q2 2025 and has held it in 5 quarters since. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Arch Venture Management held 12,694,163 shares of Vir Biotechnology worth $129M as of Q2 2026.
  • Arch Venture Management sold 222,500 Vir Biotechnology shares in Q2 2026, an estimated $2.12M.
  • Vir Biotechnology made up 11.76% of Arch Venture Management's portfolio in Q2 2026, its #6 holding.
  • Arch Venture Management first reported a position in Vir Biotechnology in Q2 2025 and has held it in 5 quarters since.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Arch Venture Management's 13F filing for Q2 2026, filed 14 Aug 2026.